Biological Psychology Links

By RANDI HUTTER EPSTEIN, M.D. NEW HAVEN — Two floors below the main level of Yale’s medical school library is a room full of brains. No, not the students. These brains, more than 500 of them, are in glass jars. They are part of an extraordinary collection that might never have come to light if not for a curious medical student and an encouraging and persistent doctor. The cancerous brains were collected by Dr. Harvey Cushing, who was one of America’s first neurosurgeons. They were donated to Yale on his death in 1939 — along with meticulous medical records, before-and-after photographs of patients, and anatomical illustrations. (Dr. Cushing was also an accomplished artist.) His belongings, a treasure trove of medical history, became a jumble of cracked jars and dusty records shoved in various crannies at the hospital and medical school. Until now. In June 2010, after a colossal effort to clean and organize the material — 500 of 650 jars have been restored — the brains found their final resting place behind glass cases around the perimeter of the Cushing Center, a room designed solely for them. These chunks of brains floating in formaldehyde bring to life a dramatic chapter in American medical history. They exemplify the rise of neurosurgery and the evolution of 20th-century American medicine — from a slipshod trial-and-error trade to a prominent, highly organized profession. Copyright 2010 The New York Times Company

By Jason Palmer The brain appears to be a vastly interconnected network much like the Internet, according to new research. That runs counter to the 19th-Century "top-down" view of brain structure. A novel technique to track signals across tiny brain regions has revealed connections between regions associated with stress, depression and appetite. The research, which has been published in Proceedings of the National Academy of Sciences journal, may lead to a full map of the nervous system. Larry Swanson and Richard Thompson from the University of Southern California in Los Angeles, US, isolated a small section of a rat's brain in the nucleus accumbens - a brain region long associated with pleasure and reward. Their technique hinges on the injection of "tracers" at precise points in the brain tissue. These are molecules that do not interfere with the movement of signals across the tissue, but can be illuminated and identified using a microscope. What is new is that the researchers injected two tracers at the same point at the same time: one that showed where signals were going, and one that showed where they were coming from. The approach can show up to four levels of connection. If the brain has a hierarchichal structure like a large company, as neurology has long held, the "to" and "from" diagram would show straight lines from independent regions up towards a central processing unit: the company's boss. (C)BBC

Regions of the brain are known to differ in people with autism. Red and orange show areas that are thicker or larger, while the blue shows a reduction in size compared with a non-autistic brain. Regions of the brain are known to differ in people with autism. Red and orange show areas that are thicker or larger, while the blue shows a reduction in size compared with a non-autistic brain. (MRC) Autism in adults can be diagnosed using MRI brain scans, British scientists have found. The 15-minute scans were used to identify autism spectrum disorder (ASD) with an accuracy of 90 per cent in 20 people who were previously diagnosed. "Our study offers a 'proof of concept' for describing the complex multidimensional grey matter differences in ASD," Dr. Christine Ecker, a lecturer in forensic and neurodevelopmental sciences at London's Institute of Psychiatry and her co-authors concluded in Wednesday's issue of the Journal of Neuroscience. In the experiment, magnetic resonance imaging scans were reconstructed into 3-D images and analyzed using computer software programmed to spot structural changes in the brain's grey matter by measuring areas that relate to behaviour, language and vision. Changes in shape and thickness point to the disorder. A capability to diagnose ASD based on objective biological tests rather than the current method of relying on personality traits could help identify patients more quickly who need treatment, Ecker said. © CBC 2010

By Dan Vergano, USA TODAY If something offers easy answers for not-so-easy questions, you might be reading a popular science book. Malcom Gladwell's Outliers: The Story of Success, centers around the idea of practicing anything for 10,000 hours to be a genius. SuperFreakonomics: Global Cooling, Patriotic Prostitutes, and Why Suicide Bombers Should Buy Life Insurance discovers that economics explains terrorism and climate change. Sex at Dawn suggests evolution explains straying spouses. And then there's Delusions of Gender: How Our Minds, Society and Neurosexism Create Difference by Cordelia Fine. A research associate at the Centre for Agency, Values and Ethics at Australia's Macquarie University, Fine turns the popular science book formula on its head. Chapter-by-chapter, she introduces ideas about the innate differences between the sexes — "it's all fetal hormones" or "men have better-wired brains" or "brain scans show men's brains light up differently" — and then tartly smacks around the studies supposedly supporting them. In particular, Fine joins critics, such as Nikos Logothetis of Germany's Max Planck Institute for Biological Cybernetics, to argue that brain images constructed from functional magnetic resonance imaging studies, often on just a few dozen people at most, have become the latest way to slap a scientific-sounding paint job on old ideas about women being intrinsically dumber than men. "The main message of the book is that our comforting beliefs about gender — that everything's fair now, that sex inequality should be blamed on 'hardwired' differences between the sexes, and that our failure to rear unisex children just points the same way — just don't bear up to scrutiny," Fine says, by e-mail. Copyright 2010 USA TODAY,

by Graham Lawton and Clare Wilson Why ask people what they think of a product when you can just scan their brains instead? New Scientist explores the brave new world of neuromarketing TAKE A look at the cover of this week's New Scientist magazine (right). Notice anything unusual? Thought not, but behind the scenes your brain is working overtime, focusing your attention on the words and images and cranking up your emotions and memory. How do we know? Because we tested it with a brain scanner. In what we suspect is a world first, this week's cover was created with the help of a technique called neuromarketing, a marriage of market research and neuroscience that uses brain-imaging technology to peek into people's heads and discover what they really want. You may find that sinister. What right does anyone have to try to read your mind? Or perhaps you are sceptical and consider the idea laughable. But neuromarketing, once dismissed as a fad, is becoming part and parcel of modern consumer society. So we decided to take a good look at it - and try it out ourselves. That is how several New Scientist readers ended up in a darkened room in London, wired up to an electroencephalograph (EEG) machine and being shown various magazine cover designs. Our aim - with the help of the European arm of neuromarketing company NeuroFocus, based in Berkeley, California - was to observe their reactions on a level that would not normally be possible. "I've been involved in market research for about 25 years," says Thom Noble, managing director of NeuroFocus Europe. "Every few years a new methodology comes out. Frankly, they're incrementally different. This is transformationally different." © Copyright Reed Business Information Ltd.

By GINA KOLATA Will Alzheimer’s disease, a terrible degenerative brain disease with no treatments and no clear guidelines for diagnosis before its end stages, become like heart disease? That might mean early markers of risk, analogous to high cholesterol levels, that predict who is likely to get it. And it might mean drugs that actually prevent it. That is the hope behind new diagnostic guidelines being proposed by the National Institute on Aging and the Alzheimer’s Association. In July, when the groups first announced their proposed guidelines, they were met with some skepticism and anger. Why suggest ways of diagnosing the disease before a person even has symptoms? Why tell people they are doomed? And are those early diagnosis guidelines just a sop to pharmaceutical companies so they can start marketing expensive, and perhaps not very effective, new drugs? So the Alzheimer’s Association, with participation from the National Institute on Aging, held a conference call on Wednesday to clarify their position. They wanted, in particular, to explain why they advocated using so-called biomarkers, like scans for amyloid plaque in the brain, a unique feature of Alzheimer’s, and tests of cerebrospinal fluid. Such brain scans are still experimental. Copyright 2010 The New York Times Company

By WALT BOGDANICH When Alain Reyes’s hair suddenly fell out in a freakish band circling his head, he was not the only one worried about his health. His co-workers at a shipping company avoided him, and his boss sent him home, fearing he had a contagious disease. Only later would Mr. Reyes learn what had caused him so much physical and emotional grief: he had received a radiation overdose during a test for a stroke at a hospital in Glendale, Calif. Other patients getting the procedure, called a CT brain perfusion scan, were being overdosed, too — 37 of them just up the freeway at Providence Saint Joseph Medical Center in Burbank, 269 more at the renowned Cedars-Sinai Medical Center in Los Angeles and dozens more at a hospital in Huntsville, Ala. The overdoses, which began to emerge late last summer, set off an investigation by the Food and Drug Administration into why patients tested with this complex yet lightly regulated technology were bombarded with excessive radiation. After 10 months, the agency has yet to provide a final report on what it found. But an examination by The New York Times has found that radiation overdoses were larger and more widespread than previously known, that patients have reported symptoms considerably more serious than losing their hair, and that experts say they may face long-term risks of cancer and brain damage. Copyright 2010 The New York Times Company

Miriam Frankel A type of brain cell thought to be responsible for supporting other cells may have a previously unsuspected role in controlling breathing. Star-shaped cells called astrocytes, found in the brain and spinal cord, can 'sense' changes in the concentration of carbon dioxide in the blood and stimulate neurons to regulate respiration, according to a study published online in Science today1. The research may shed some light on the role of astrocytes in certain respiratory illnesses, such as cot death, which are not well understood. Astrocytes are a type of glial cell — the most common type of brain cell, and far more abundant than neurons. "Historically, glial cells were only thought to 'glue' the brain together, providing neuronal structure and nutritional support but not more," explains physiologist Alexander Gourine of University College London, one of the authors of the study. "This old dogma is now changing dramatically; a few recent studies have shown that astrocytes can actually help neurons to process information." "The most important aspect of this study is that it will significantly change ideas about how breathing is controlled," says David Attwell, a neuroscientist at University College London, who was not involved in the study. During exercise, the amount of CO2 in the blood increases, making the blood more acidic. Until now, it was thought that this pH change was 'sensed' by specialized neurons that signal to the lungs to expel more CO2. But the study found that astrocytes can sense such a decrease in pH too — a change that causes an increase in the concentration of calcium ions (Ca2+) in the cells and the release of the chemical messenger adenosine-5'-triphosphate (ATP). © 2010 Nature Publishing Group,

By GINA KOLATA A small company with a new brain scan for detecting plaque, the hallmark physical sign of Alzheimer’s disease, presented its results on Sunday at an international conference in Hawaii, and experts who attended said the data persuaded them that the method works. Until now, the only definitive way to diagnose Alzheimer’s has been to search for plaque with a brain autopsy after the patient dies. Scientists hope the new scanning technique, described June 24 in The New York Times’s series “The Vanishing Mind,” will allow doctors to see plaque while the patient is still alive, improving diagnosis and aiding research on drugs to slow or stop plaque accumulation. Neurologists have known about plaques ever since Alzheimer’s disease was first described in 1906. They are microscopic bumps made up of a protein, amyloid beta, appearing on the surface of the brain in areas involved with learning and memory. They are so characteristic of Alzheimer’s that they are required for a definitive diagnosis of the disease. Of course, doctors do not wait for a brain autopsy to diagnose Alzheimer’s. They use memory tests and evaluations of patients’ reasoning and ability to care for themselves. Yet with autopsy, even doctors at leading medical centers have been wrong as often as 20 percent of the time: people they said had Alzheimer’s did not have plaque. Copyright 2010 The New York Times Company

By GINA KOLATA Dr. Daniel Skovronsky sat at a small round table in his corner office, laptop open, waiting for an e-mail message. His right leg jiggled nervously. A few minutes later, the message arrived — results that showed his tiny start-up company might have overcome one of the biggest obstacles in diagnosing Alzheimer’s disease. It had found a dye and a brain scan that, he said, can show the hallmark plaque building up in the brains of people with the disease. The findings, which will be presented at an international meeting of the Alzheimer’s Association in Honolulu on July 11, must still be confirmed and approved by the Food and Drug Administration. But if they hold up, it will mean that for the first time doctors would have a reliable way to diagnose the presence of Alzheimer’s in patients with memory problems. And researchers would have a way to figure out whether drugs are slowing or halting the disease, a step that “will change everyone’s thinking about Alzheimer’s in a dramatic way,” said Dr. Michael Weiner of the University of California, San Francisco, who is not part of the company’s study and directs a federal project to study ways of diagnosing Alzheimer’s. Still, the long tale behind this finding shows just how difficult this disease is and why progress toward preventing or curing it has been so slow. Ever since Alzheimer’s disease was described by a German doctor, Alois Alzheimer, in 1906, there was only one way to know for sure that a person had it. A pathologist, examining the brain after death, would see microscopic black freckles, plaque, sticking to brain slices like barnacles. Without plaque, a person with memory loss did not have the disease. Copyright 2010 The New York Times Company

Currently, mind-robbing disease only diagnosed at autopsy MSNBC NEWS SERVICES — A new imaging agent that homes in on the gummy plaques and tangles that jam up the brains of Alzheimer’s patients has allowed doctors to see the disease in a living person for the first time, researchers said Wednesday. The mind-robbing disease, which is always fatal and has no cure, can now only be definitively diagnosed by looking at the brain after a patient has died. IN THE NEW study, the researchers were able to view the messy clumps of dead cells in the brains of nine living Alzheimer’s patients. The finding means that Alzheimer’s, which affects 4 million Americans and millions more around the world, may be diagnosed in the early stages, when treatments might be able to do some good, said Jorge Barrio of the University of California Los Angeles, who helped lead the study. MSNBC Terms and Conditions © 2002

Researchers say PET scans can help diagnosis, treatment ANN ARBOR, MI – Even though Alzheimer's disease takes a terrible toll on the memories and lives of millions of adults each year, doctors often face great uncertainty when trying to diagnose it in living people. Several other diseases can mimic the symptoms of Alzheimer's disease, and only an autopsy can confirm a diagnosis for certain. The lack of a definitive Alzheimer's test didn't matter so much in the past, but in recent years new drugs and therapies have been shown to slow the spiral of memory loss and behavior changes that Alzheimer's patients face. A good new diagnostic test could help patients get help early -- and make the most of their remaining years. That's why University of Michigan Health System researchers and others are so excited about a kind of medical imaging that they think can tell Alzheimer's disease apart from other disorders. By looking at the brain with a special camera, they hope to give patients a more definitive diagnosis while they can still do something about it.

Research indicates that astrocytes may play key role in build-up, degradation of Alzheimer’s proteins New York, NY – – A new study from Columbia University College of Physicians and Surgeons (P&S) and Stanford University suggests that the malfunctioning of brain cells called astrocytes may be behind the accumulation of amyloid protein in the brains of patients with Alzheimer’s disease. Alzheimer’s disease, most researchers believe, is caused when small peptides called beta-amyloid accumulate in the brain. Everyone makes these peptides at all times during their life, but in people with Alzheimer’s, either too much is made or too little is degraded or both. The resulting excess of peptides aggregate together in plaques. Beta-amyloid plaques then lead to death of neurons and dementia. Researchers have known that microglia cells in the brain, which surround the plaques, can ingest and destroy the plaque’s proteins in cell culture, so they’ve been trying to stimulate the cells to do so in vivo. But the role of other cells that surround the plaques, the astrocytes, hasn’t been clear. The new findings show that normal astrocytes can also degrade plaque proteins, suggesting that treatments to boost astrocyte activity in Alzheimer’s disease may be beneficial. The study is published in the advanced online edition of Nature Medicine and will be featured in the April issue of the publication.

RESTON, Va.—Using both brain function (PET) and anatomical structure (MR) imaging studies, Italian researchers—within the context of an Italian-British collaboration—discovered that degenerative and dysfunctional events occur in individuals many years before the onset of Huntington’s disease—particularly in the brain’s white matter—an area not previously considered primarily involved with the disease. In fact, the brain’s white matter “progressively reduced” as individuals approached the first disease symptoms, according to a study published in February’s Journal of Nuclear Medicine. “Our observations—made by analyzing the results of the largest group of subjects studied to date—may suggest new methodologies and drug trials for therapy,” said Ferdinando Squitieri, M.D., Ph.D., who works in the Neurogenetics Unit and Centre for Rare Diseases of IRCCS Neuromed in Pozzilli, Isernia, Italy. “It is possible to approach the disease at the presymptomatic stage by monitoring the brain tissue volumes and the basal ganglia and cortex dysfunction. If so, we may be able to prevent Huntington’s disease before onset symptoms by using proper drugs,” added the co-author of “Brain White-Matter Volume Loss and Glucose Hypometabolism Precede the Clinical Symptoms of Huntington’s Disease.” Copyright © 2006 SNM

SAN DIEGO, Calif.—A team of Johns Hopkins researchers developed a new radiotracer—a radioactive substance that can be traced in the body—to visualize and quantify the brain’s cannabinoid receptors by positron emission tomography (PET), opening a door to the development of new medications to treat drug dependence, obesity, depression, schizophrenia, Parkinson’s disease and Tourette syndrome. Discovery of the [11C]JHU75528 radioligand, a radioactive biochemical substance that is used to study the receptor systems of the brain, “opens an avenue for noninvasive study of central cannabinoid (CB1) receptors in the human and animal brain,” explained Andrew Horti, assistant professor of radiology at Johns Hopkins Medicine, Baltimore, Md. He explained that there is evidence that CB1 receptors play an essential role in many disorders including schizophrenia, depression and motor function disorders. “Quantitative imaging of the central CB1 using PET could provide a great opportunity for the development of cannabinergic medications and for studying the role of CB1 in these disorders,” added the co-author of “PET Imaging of Cerebral Cannabinoid CB1 Receptors with [11C]JHU75528.” Cannabinoid receptors are proteins on the surface of brain cells; they are most dense in brain regions involved with thinking and memory, attention and control of movement. The effects of tetrahydrocannabinol (THC), the primary psychoactive compound in marijuana, are due to its binding to specific cannabinoid receptors located on the surface of brain cells. “Blocking CB1 receptors presents the possibility of developing new, emerging medications for treatment of obesity and drug dependence including alcoholism, tobacco and marijuana smoking,” said Horti. © 2006 SNM

After Susan Zilber's father died from Alzheimer's disease she wanted to know if she'd share his fate. "Information is key to figuring out how you're going to deal with something," she says. "That's part of who I am, and I think that I'd be able to deal with it. I'd rather know than not know." The problem is, there isn't a single test for Alzheimer's. Now, researchers have developed new software, called HipMask, that can potentially assess a person's risk for cognitive impairment by scanning of a tiny brain area called the hippocampus, which is known to be affected in the early stages of Alzheimer's. When applied to patient PET and MRI scans taken over the course of a longitudinal study of Alzheimer's, the software proved to be 85 percent accurate in predicting who would get the disease nine years before patients showed symptoms. "What we are trying to do is to find the measure that would predict decline from normal aging to Alzheimer's disease," explains Lisa Mosconi, a brain researcher at New York University School of Medicine's Center for Brain Health. "It looks like the hippocampus is particularly involved in early Alzheimer's disease, so by studying how the hippocampus [is working] in Alzheimer's patients — or in Alzheimer's patients it's actually not working — we can probably find a predictor for Alzheimer's disease." © ScienCentral, 2000-2006.

Alzheimer’s disease researchers may be able to reduce the time and expense associated with clinical trials, according to early results from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a public-private research partnership organized by the National Institutes of Health. Preliminary results from ADNI show how it might yield improved methods and uniform standards for imaging and biomarker analysis, so these techniques can be employed in the fight against Alzheimer’s disease. These first findings will be presented at the Alzheimer’s Association International Conference on the Prevention of Dementia being held in Washington, D.C., June 9-12. The ADNI study observes and tracks changes in normal individuals, in people with mild cognitive impairment — a condition which often precedes Alzheimer’s — and in people with Alzheimer’s. Researchers will use PET (positron emission tomography) and MRI (magnetic resonance imaging) scans to track changes in the brain, laboratory analyses of cerebrospinal fluid and blood to study biomarkers, and clinical interviews to track cognitive performance over time. ADNI is expected to improve neuroimaging and biomarker measures and consequently allow faster and more efficient evaluation of potential therapies for Alzheimer’s. The $60 million, five-year study began recruiting in early 2006, and today about 800 older people at 58 sites in the United States and Canada participate in the effort.

It seems simple. We get hungry and we eat. But eating is much more complex than that, and scientists are only starting to understand the many factors that regulate eating behavior. One of these factors is stomach expansion that sends signals to the brain resulting in feelings of fullness. Nuclear medicine physician Gene-Jack Wang and colleagues at Brookhaven National Laboratory wanted to find out why it takes different volumes of food to satisfy different people. This is where the water balloons come in. The researchers asked 18 healthy volunteers with body mass indices (BMI) ranging from 20 (low/normal weight) to 29 (extremely overweight/borderline obese) to swallow a balloon connected to a water tube. The balloon assembly is actually a plain-end, non-lubricated latex condom securely connected to a tube with unwaxed dental floss. In order to make it easier to swallow, volunteers were first asked to put small plastic mouthpieces coated with a numbing lidocaine gel in their mouths. The volunteers then rinsed the back of their tongues with more lidocaine. Then the subjects swallowed the balloon, which ended up in their stomachs. The tube was taped to their cheeks. Before asking any volunteers to try the procedure, each of the scientists themselves tried swallowing the balloons and having it filled with water. While the brain activity of volunteers was monitored using functional magnetic imaging (fMRI), the scientists filled the balloons first with about one cup (250 ml) of body-temperature water, and then with about two cups (500 ml). A normal adult stomach can hold about 750 ml. As Wang explains, scientists knew that people respond differently to different volumes of food. © ScienCentral, 2000-2008.

By BENEDICT CAREY The outer layer of the brain, the reasoning, planning and self-aware region known as the cerebral cortex, has a central clearinghouse of activity below the crown of the head that is widely connected to more-specialized regions in a large network similar to a subway map, scientists reported Monday. The new report, published in the free-access online journal PLoS Biology, provides the most complete rough draft to date of the cortex’s electrical architecture, the cluster of interconnected nodes and hubs that help guide thinking and behavior. The paper also provides a striking demonstration of how new imaging techniques focused on the brain’s white matter — the connections between cells, rather than the neurons themselves — are filling in a dimension of human brain function that has been all but dark. In previous studies, scientists have used magnetic resonance imaging to identify peaks and valleys of neural activity when people are doing various things, like making decisions, reacting to frightening images or reliving painful memories. But these studies, while provocative, revealed virtually nothing about the underlying neural networks involved — about which brain regions speak to one another and when. Previous estimates of network structure, based on such imaging, have been sketchy. The new findings, while not conclusive, give scientists what is essentially a wiring diagram that they can test and refine. Copyright 2008 The New York Times Company

By GINA KOLATA This is a story about M.R.I.’s, those amazing scans that can show tissue injury and bone damage, inflammation and fluid accumulation. Except when they can’t and you think they can. I found out about magnetic resonance imaging tests when I injured my forefoot running. All of a sudden, halfway through a run, my foot hurt so much that I had to stop. But an M.R.I. at a local radiology center found nothing wrong. That, of course, was what I wanted to hear. So I spent five days waiting for it to feel better, taking the anti-inflammatory drugs ibuprofen and naproxen, using an elliptical cross-trainer, and riding my road bike with its clipless pedals that attach themselves to my bicycling shoes. By then, my foot hurt so much I had to walk on my heel. I was beginning to doubt that scan: it was hard to believe nothing was wrong. So I went to the Hospital for Special Surgery in New York for a second opinion from Dr. John G. Kennedy, an orthopedist who specializes in sports-related lower-limb injuries. And there I had another M.R.I. It showed a serious stress fracture, a hairline crack in a metatarsal bone in my forefoot. It was so serious, in fact, that Dr. Kennedy warned that I risked surgery if I continued activities like cycling and the elliptical cross-trainer, which make such injuries worse. And I had to stop taking anti-inflammatory drugs, since they impede bone healing. Copyright 2008 The New York Times Company

Chapter 2. Functional Neuroanatomy: The Nervous System and Behavior